Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
‘PC sales may stay sluggish in 1H23’ -DigiTimes Alert
Brand PC vendors continue to cut back orders amid high inventory levels, and may fail to see their shipments pick up until the second half of next year, according to industry sources.
